Harrow Q1 Earnings Call Highlights
Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating. On the company’s
MarketBeat ·